Prajakta Badri
Alnylam Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Hepatitis C virus research, Amyloidosis: Diagnosis, Treatment, Outcomes, HIV/AIDS drug development and treatment, Liver Disease Diagnosis and Treatment, Protein Kinase Regulation and GTPase Signaling
Most-Cited Works
- → An Interferon-free Antiviral Regimen for HCV after Liver Transplantation(2014)402 cited
- → Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial(2022)351 cited
- → Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis(2023)275 cited
- → Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir(2015)125 cited
- → Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT-450, Ombitasvir, and Dasabuvir(2015)83 cited
- → Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients(2015)82 cited
- → Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria(2020)73 cited
- → Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial(2024)60 cited
- → Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir(2015)42 cited
- → Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection(2014)42 cited